Warnings and precautions in the prescribing information
According to the FDA-approved prescribing information, the warnings and precautions for RASONQUE include:
- Dermatologic and soft tissue toxicity: rash (including acneiform dermatitis and maculopapular rash), dry skin, paronychia and others;
- Stomatitis and other oral disorders;
- Diarrhoea;
- Gastrointestinal perforation;
- Interstitial lung disease / pneumonitis;
- Embryo-fetal toxicity: females of reproductive potential and their male partners should use effective contraception during treatment and for a period after the last dose.
Common adverse reactions
Inhibiting wild-type RAS affects normal tissues that rely heavily on RAS signalling, such as the skin and gastrointestinal epithelium. The most common adverse reactions with daraxonrasib are therefore rash, stomatitis, diarrhoea, nausea, vomiting, fatigue and decreased appetite, most of them grade 1–2. In the Phase 1/2 NSCLC cohort, rash occurred in about 90% of patients (grade ≥3 in about 8%), diarrhoea in 73%, nausea in 62% and vomiting in 54%.
In the Phase 3 RASolute 302 trial, the rate of grade ≥3 treatment-related adverse events with daraxonrasib (43.6%) was lower than with chemotherapy (57.5%), and only 1.2% of patients discontinued because of adverse events (11.2% with chemotherapy), indicating an overall manageable safety profile that compares favourably with conventional chemotherapy.
Key points for clinical management
| Adverse reaction | Common management strategies |
|---|---|
| Rash | Start preventive care at treatment initiation: gentle cleansing, moisturising, sun protection; topical corticosteroids and oral tetracyclines (e.g. doxycycline, minocycline) according to severity; consider interruption and dose reduction for grade ≥3. |
| Stomatitis | Maintain oral hygiene, use alcohol-free mouthwash or dexamethasone rinse, avoid irritating foods; interrupt treatment for severe events. |
| Diarrhoea | Prompt use of antidiarrhoeals such as loperamide, fluid replacement and dietary adjustment; persistent grade ≥3 events require interruption and evaluation. |
| Nausea / vomiting | Antiemetics as needed; coordinate meal timing with dosing. |
| Interstitial lung disease / pneumonitis | Evaluate promptly for new or worsening respiratory symptoms; permanently discontinue if confirmed and treat with corticosteroids. |
Special populations
- Pregnancy and lactation: based on its mechanism of action, the drug may cause fetal harm and is not recommended during pregnancy; breastfeeding should be avoided.
- Hepatic and renal impairment: data in moderate-to-severe impairment are limited; refer to the prescribing information.
- Drug interactions: be aware of interactions with strong CYP3A inhibitors/inducers; see the prescribing information.